18. Lartruvo

FDA sign

Active ingredient: olaratumab
Disease: certain types of soft tissue sarcoma
Peak sales estimate: n/a
Approved: Oct. 19
Company: Eli Lilly

The scoop: En route to its accelerated approval in October, Eli Lilly’s olaratumab seemed to rack up every possible shortcut from the FDAfast-track and breakthrough therapy designations as well as priority review and orphan drug designation. The agency OK’d the drug as a first-line treatment for soft tissue sarcoma, to be used in tandem with doxorubicin. Soft tissue sarcoma encompasses a range of tumors that occur in the muscle, fat, blood vessels, nerves, tendons or the lining of the joints. Lartruvo works by blocking platelet-derived growth factor (PDGF) receptors, which may help or delay tumor growth. The Lartruvo-doxorubicin combo is indicated for patients whose STS cannot be cured by radiation or surgery. Their disease must also be a type where an anthracycline is an appropriate treatment. Lartruvo is the first new drug to be approved as an initial treatment for STS in four decades. Meanwhile, Johnson & Johnson’s Yondelis earned its long-awaited FDA nod a year prior for the treatment of two types of STS that affect smooth muscle and fat cells. -- Amirah Al Idrus

18. Lartruvo

Suggested Articles

Medimmune’s Ronald Herbst, Ph.D., has followed a series of other AstraZeneca and its biologics arm staffers out the door.

The takeover will give Alexion two clinical-phase medicines in development in complement alternative pathway-mediated rare diseases.

Last year, Eli Lilly spent $1.6 billion to get its hands on Armo Biosciences and its lead asset, pegilodecakin. Today, that drug flopped.